Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Intellia Therapeutics to post earnings of ($1.39) per share and revenue of $8.10 million for the quarter.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.28 on Thursday. The stock has a 50-day simple moving average of $11.07 and a two-hundred day simple moving average of $16.12. Intellia Therapeutics has a 52-week low of $8.96 and a 52-week high of $34.87. The firm has a market capitalization of $1.25 billion, a PE ratio of -2.26 and a beta of 1.80.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of recent analyst reports. Oppenheimer dropped their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $56.00 to $11.00 in a research note on Monday, January 27th. William Blair reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. Wells Fargo & Company dropped their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Finally, The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.